ARMP — Armata Pharmaceuticals, Inc.

—
NYSE · Health Care · Biotechnology · CIK 921114 ·
Last close
$2.66
Market Cap
$98.93M
52W High
$14.98
52W Low
$2.40
ADV30
95,596
Next earnings
—
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -7,383,000 54,857,000 84,478,000 18,317,000 258,606,000
Jun 2026 — — — — — — —
Mar 2026 0 — -8,785,000 -115,346,000 69,800,000 4,754,000 381,386,000
Dec 2025 0 — -8,411,000 -124,298,000 76,882,000 8,688,000 295,478,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-23,965,000
Investing CF
$-506,000
Financing CF
$16,267,000
CapEx
$-506,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-616,880,000
Inventory
—
Receivables
$47,000
ST Investments
—
EBIT TTM
$-264,067,000
Pretax Income TTM
$-282,614,000
Interest Exp TTM
$18,547,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,555,000
EBITDA
$-32,853,000
Free Cash Flow
$-30,552,376
Enterprise Value
$377,201,472
Total Cash
$18,317,000
Total Debt
$251,583,008
Shares Out
37,192,632
Trailing EPS
$-4.17
Book Value
$-4.68
ROE
—
ROA
-25.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -31,222,000 -173,799,000 76,882,000 295,478,000 -218,596,000 -25,763,000
Dec 2024 0 -42,436,000 -18,916,000 86,437,000 134,456,000 -48,019,000 -37,551,000
Dec 2023 0 -40,890,000 -69,045,000 98,363,000 130,428,000 -32,065,000 -47,423,000
Dec 2022 0 -36,946,000 -36,917,000 95,834,000 59,754,000 36,080,000 -32,481,000

TTM Snapshot

Revenues TTM
$5,543,000
NetIncome TTM
$-192,178,000
OpCashFlow TTM
—
Assets (Latest)
$89,950,000
Forward EPS
$-2.04

Peers — same industry

TickerNameMarket CapLastDaily %
ZURA Zura Bio Ltd $99.70M $1.03 —
VYGR Voyager Therapeutics, Inc. $94.59M $1.52 —
CMPX Compass Therapeutics, Inc. $109.26M $0.61 —
MOLN MOLECULAR PARTNERS AG $109.55M $2.86 —
LENZ LENZ Therapeutics, Inc. $109.97M $3.50 —

News headlines (Yahoo Finance, 1h cache)

Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
2026-11-12 21:05 · Yahoo
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
2026-10-07 11:00 · Yahoo
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
2026-09-23 11:00 · Yahoo
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
2026-09-21 11:00 · Yahoo
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
2026-09-14 13:34 · Yahoo
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
2026-09-14 11:00 · Yahoo
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 11:00 · Yahoo
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
2026-09-03 11:00 · Yahoo
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
2026-07-21 11:05 · Yahoo
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
2026-07-20 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.